Skip to content

GARDE : GC7 (N1-guanyl-1,7 Diaminoheptane) cARDiac arrEst

Impact of GC7 (N1-guanyl-1,7 Diaminoheptane) on Oxidative Stress in Patients Who Have Experienced a Resuscitated Cardiorespiratory Arrest

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07468292
Acronym
GARDE
Enrollment
20
Registered
2026-03-12
Start date
2026-07-01
Completion date
2028-12-01
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac Arrest (CA)

Keywords

cardiac arrest, GC7 (N1-guanyl-1,7 diaminoheptane), oxidative stress

Brief summary

Cardiac arrest (CA) with return of spontaneous circulation is associated with high mortality, exceeding 90% in out-of-hospital settings and approaching 50% in in-hospital settings. Despite management of the underlying cause of CA, patients often die from post-anoxic brain injury or from ischemia-reperfusion injury occurring after reperfusion and reoxygenation, which increases oxidative stress and leads to multi-organ failure. To date, no effective therapeutic strategy has been established in humans to limit these ischemia-reperfusion injuries. GC7 (N1-guanyl-1,7 diaminoheptane) has demonstrated a strong protective potential against ischemia reperfusion injury in rodent and porcine models, including myocardial infarction, stroke, and renal transplantation. These protective effects are attributed to the pleiotropic action of GC7 which renders cells and tissues energetically less dependent on oxygen, and reduces oxidative stress which play a major role in ischemia reperfusion injury. Degree of blood acidification and immune dysregulation may also represent parameters that GC7 could potentially influence. Although no adverse effects have been reported in these experimental models, GC7 has not yet been studied in human. Our study therefore aims to demonstrate the protective effect of GC7 on blood cells in patients after CA by evaluating oxidative stress levels, blood acidification and inflammatory profile.

Interventions

OTHERGC7 exposure

24-hour exposure of patient 's blood to GC7 molecule

OTHERNo GC7 exposure

No exposure of blood to GC7 molecule

Sponsors

Centre Hospitalier Universitaire de Nice
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Cardiac arrest as the primary reason for hospital admission * Admission \< 48 hours * Age ≥ 18 years * Affiliated with a social security system

Exclusion criteria

* Limitation or withdrawal of life-sustaining therapies prior to study screening * Prior cardio-vascular ischemic event (\> 24h) before cardiac arrest * Patient deprived of liberty

Design outcomes

Primary

MeasureTime frame
Blood oxidative stress levelsat 24 hours after blood exposure to GC7

Secondary

MeasureTime frame
Blood acidification24 hours after blood exposure to GC7
Blood inflammatory profile24 hours after blood exposure to GC7

Countries

France

Contacts

CONTACTDenis DOYEN, MD
doyen.d@chu-nice.fr+33492033615
CONTACTDOMINIQUE DONZEAU
donzeau.d@chu-nice.fr+33492034560

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 17, 2026